Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature

Olsson, 2006, VEGF receptor signalling—in control of vascular function, Nat Rev Mol Cell Biol, 7, 359, 10.1038/nrm1911 Ferrara, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Izzedine, 2007, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension, Am J Kidney Dis, 50, 203, 10.1053/j.ajkd.2007.04.025 Gressett, 2009, Intricacies of bevacizumab-induced toxicities and their management, Ann Pharmacother, 43, 490, 10.1345/aph.1L426 Eremina, 2008, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 358, 1129, 10.1056/NEJMoa0707330 Eremina, 2010, Biology of anti-angiogenic therapy-induced thrombotic microangiopathy, Semin Nephrol, 30, 582, 10.1016/j.semnephrol.2010.09.006 Bollee, 2009, Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib, Nephrol Dial Transplant, 24, 682, 10.1093/ndt/gfn657 Costero, 2010, Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy, Nephrol Dial Transplant, 25, 1001, 10.1093/ndt/gfp666 Frangie, 2007, Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma, Lancet Oncol, 8, 177, 10.1016/S1470-2045(07)70037-2 Izzedine, 2007, Thrombotic microangiopathy and anti-VEGF agents, Nephrol Dial Transplant, 22, 1481, 10.1093/ndt/gfl565 Overkleeft, 2010, Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib, Ann Oncol, 21, 184, 10.1093/annonc/mdp472 Roncone, 2007, Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma, Nat Clin Pract Nephrol, 3, 287, 10.1038/ncpneph0476 Stokes, 2008, Glomerular disease related to anti-VEGF therapy, Kidney Int, 74, 1487, 10.1038/ki.2008.256 Jin, 2010, Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?, Clin Transl Oncol, 12, 526, 10.1007/s12094-010-0550-4 Aparicio-Gallego, 2011, New insights into molecular mechanisms of sunitinib-associated side effects, Mol Cancer Ther, 10, 2215, 10.1158/1535-7163.MCT-10-1124 Escudier, 2011, Axitinib for the management of metastatic renal cell carcinoma, Drugs R D, 11, 113, 10.2165/11591240-000000000-00000 Schrijvers, 2004, The role of vascular endothelial growth factor (VEGF) in renal pathophysiology, Kidney Int, 65, 2003, 10.1111/j.1523-1755.2004.00621.x Ku, 2008, Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice, Diabetes, 57, 2824, 10.2337/db08-0647 Sison, 2010, Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling, J Am Soc Nephrol, 21, 1691, 10.1681/ASN.2010030295 Veron, 2010, Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease, Kidney Int, 77, 989, 10.1038/ki.2010.64 Eremina, 2003, Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, J Clin Invest, 111, 707, 10.1172/JCI17423 Eremina, 2006, Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival, J Am Soc Nephrol, 17, 724, 10.1681/ASN.2005080810 Hertig, 2008, How should women with pre-eclampsia be followed up? New insights from mechanistic studies, Nat Clin Pract Nephrol, 4, 503, 10.1038/ncpneph0880 George, 2007, Nephrotic syndrome after bevacizumab: case report and literature review, Am J Kidney Dis, 49, e23, 10.1053/j.ajkd.2006.11.024 Winn, 2009, Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?, Nephrol Dial Transplant, 24, 673, 10.1093/ndt/gfn625 Rolleman, 2009, Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma, Nephrol Dial Transplant, 24, 2002, 10.1093/ndt/gfp140 Chen, 2009, Nephrotic syndrome and acute renal failure apparently induced by sunitinib, Case Rep Oncol, 2, 172, 10.1159/000241551 Patel, 2008, A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib, J Natl Cancer Inst, 100, 282, 10.1093/jnci/djm311 McDonald, 1991, Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature, Am J Med, 90, 386, 10.1016/0002-9343(91)90582-I Glezerman, 2011, Kidney tubular toxicity of maintenance pemetrexed therapy, Am J Kidney Dis, 58, 817, 10.1053/j.ajkd.2011.04.030 Glezerman, 2009, Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution, Clin Nephrol, 71, 130, 10.5414/CNP71130 Dlott, 2004, Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review, Ther Apher Dial, 8, 102, 10.1111/j.1526-0968.2003.00127.x